IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0683301
(2012-11-21)
|
등록번호 |
US-9174948
(2015-11-03)
|
발명자
/ 주소 |
- Bergeron, Jr., Raymond J.
|
출원인 / 주소 |
- University of Florida Research Foundation, Inc.
|
대리인 / 주소 |
Wolf, Greenfield & Sacks, P.C.
|
인용정보 |
피인용 횟수 :
5 인용 특허 :
67 |
초록
▼
A relatively non-toxic desazadesferrithiocin analog having the formula: wherein: R1, R2, R4 and R5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl and butyl, or arylalkyl wherein the aryl portion is hydrocarbyl and
A relatively non-toxic desazadesferrithiocin analog having the formula: wherein: R1, R2, R4 and R5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl and butyl, or arylalkyl wherein the aryl portion is hydrocarbyl and the alkyl portion is straight or branched chain, the arylalkyl group having up to 14 carbon atoms, R2 optionally being alkoxy having up to 14 carbon atoms; R3 is (CH2)n—Ox—(CH2)n—Oy-alkyl;n is, independently, an integer from 1 to 8;x is an integer from 1 to 8;y is an integer from 0 to 8, andR3O may occupy any position on the phenyl ring except the 4-position, ora salt, hydrate or solvate thereof; and methods and compositions for treating the effects of trivalent metal, i.e., iron, overload.
대표청구항
▼
1. A desazadesferrithiocin analog of the formula: wherein: R1, R4, and R5 are the same or different and are H, straight or branched chain alkyl having up to 14 carbon atoms, or arylalkyl wherein the aryl portion is hydrocarbyl, the alkyl portion is straight or branched chain, and the arylalkyl grou
1. A desazadesferrithiocin analog of the formula: wherein: R1, R4, and R5 are the same or different and are H, straight or branched chain alkyl having up to 14 carbon atoms, or arylalkyl wherein the aryl portion is hydrocarbyl, the alkyl portion is straight or branched chain, and the arylalkyl group has up to 14 carbon atoms;R2 is H, straight or branched chain alkyl having up to 14 carbon atoms, alkoxy having up to 14 carbon atoms, or arylalkyl wherein the aryl portion is hydrocarbyl, the alkyl portion is straight or branched chain, and the arylalkyl group has up to 14 carbon atoms;R3 is —[(CH2)n—O]x—[(CH2)n—O]y-alkyl;n is, independently, an integer from 1 to 8;x is 3;y is 0; and—OR3 occupies the 3-position on the phenyl ring; or a salt, hydrate, or solvate thereof. 2. An analog of claim 1 wherein R1 is H or —CH3. 3. An analog of claim 1 wherein R2 is H or —OCH3. 4. An analog of claim 1 wherein —OR3 is —O—[(CH2)2—O]3—CH3. 5. A pharmaceutical composition comprising at least one analog of claim 1, or a salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier therefor. 6. A pharmaceutical composition of claim 5, wherein R1 is H or —CH3. 7. A pharmaceutical composition of claim 5, wherein R2 is H or —OCH3. 8. A pharmaceutical composition of claim 5, wherein —O—R3 is —O—[(CH2)2—O]3—CH3. 9. The analog of claim 1, wherein R4 and R5 are each H. 10. (R)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxyl)phenyl]-4-methyl-4-thiazolecarboxylic acid, or a salt, hydrate, or solvate thereof. 11. A mixture of (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxyl)phenyl]-4-methyl-4-thiazolecarboxylic acid, or a salt, hydrate, or solvate thereof, and (R)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxyl)phenyl]-4-methyl-4-thiazolecarboxylic acid, or a salt, hydrate, or solvate thereof. 12. The mixture of claim 11, wherein said mixture is racemic. 13. A pharmaceutical composition comprising the compound of claim 10, or a salt, hydrate, or solvate thereof, and optionally a pharmaceutically acceptable carrier. 14. A pharmaceutical composition comprising the mixture of claim 11, and optionally a pharmaceutically acceptable carrier. 15. The pharmaceutical composition of claim 14, wherein said mixture is racemic. 16. An analog of claim 1, wherein R1 is —CH3. 17. An analog of claim 1, wherein R2 is H. 18. An analog of claim 1, wherein each instance of n is 2. 19. A pharmaceutical composition of claim 5, wherein R1 is —CH3. 20. A pharmaceutical composition of claim 5, wherein R2 is H. 21. A pharmaceutical composition of claim 5, wherein each of R4 and R5 is H. 22. A pharmaceutical composition of claim 5, wherein each instance of n is 2. 23. An analog of claim 1, wherein the salt is an alkali or alkaline earth metal salt. 24. An analog of claim 1, wherein the salt is a sodium salt, potassium salt, magnesium salt, or calcium salt.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.